# StemBioSys

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stembiosys

- Industry: Biotechnology
- Headquarters: San Antonio, US
- Website: www.stembiosys.com
- Total disclosed funding: $8M
- Latest round: Series A (Apr 14, 2015)
- Investors on record: 1

## About

StemBioSys, Inc. is a biotechnology company focused on pioneering cell culture technologies that enhance research in cardiac and regenerative medicine.Founded in 2010 and headquartered in San Antonio, US, StemBioSys, Inc. specializes in advanced cell culture solutions. The company has completed five deals with its latest funding round taking place in May 2019, where it raised USD 1.39 mn. Robert Hutchens serves as the CEO, leading the firm’s innovative approaches in cellular technologies.StemBioSys, Inc. specializes in innovative cell culture technologies, with its primary product offerings centered around the CELLvo™ Matrix Plus. This next-generation cellular matrix technology is designed to create a biologically relevant environment that mimics the native extracellular matrix, thereby supporting the maturation and functionality of various cell types, particularly induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). The CELLvo™ Matrix Plus facilitates the generation of structurally mature cardiomyocytes, which are crucial for preclinical drug safety testing and cardiotoxicity screening. The products are tailored for use in research settings, primarily targeting biopharmaceutical companies, academic institutions, and other entities involved in cardiac research and drug development. StemBioSys aims to serve customers in North America, Europe, and Asia, capitalizing on the increasing global demand for advanced cell culture solutions.The revenue generation model for StemBioSys is primarily structured around the direct sale of CELLvo™ Matrix Plus and related products to research institutions and pharmaceutical companies. Transactions typically involve one-time purchases of products, with options for custom coating services for cell culture plates and flasks. The pricing structure for CELLvo™ Matrix products reflects their premium positioning in the market, facilitating high-throughput testing and research applications. The company’s clientele includes both academic and corporate customers who engage in B2B transactions, often purchasing in bulk to meet the needs of ongoing research projects. As the demand for reliable, innovative cell culture technologies continues to rise, StemBioSys is strategically positioned to enhance its market presence and drive revenue through its flagship CELLvo™ product line.StemBioSys, Inc. plans to leverage its recent funding of USD 1.39 mn, raised in May 2019, to support the development and launch of new products within the CELLvo™ line. The company is actively exploring opportunities to expand its market reach into Europe and Asia by 2023, focusing on partnerships with biopharmaceutical companies and academic research institutes. These strategic initiatives aim to address the growing global demand for specialized cell culture technologies.

## Funding rounds

- Series A, Apr 14, 2015, $8M — Targeted Technology

## Investors

- Targeted Technology (https://capitalatlas.ai/funds/targeted-technology) — Series A